NCT05124210View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

PHASE2TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Sotrovimab

Sotrovimab will be administered.

Trial Locations (2)

85210

GSK Investigational Site, Mesa

35055-1921

GSK Investigational Site, Cullman

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

collaborator

Vir Biotechnology, Inc.

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT05124210 - Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter